Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2026 event, please get in touch at info@hansonwade.com
Other Events in the Series:
Heralding a New Era of CNS-Targeted Oligonucleotides to the Clinic & Beyond
Uniting CNS Biotech & Pharma to Fuel the Next Wave of Oligonucleotide Drug Discovery, Translation & Clinical Progress
With clinical momentum from Eli Lilly’s lipidated brain shuttle siRNAs, Alnylam Pharmaceuticals’ ALN-APP siRNA, Wave’s Phase 1b/2a positive SELECT-HD data, 170+ biotech and 30+ pharma active in the field, and a surge of novel approaches, the oligonucleotide field showed no signs of slowing down.
The 5th Oligonucleotides for CNS Summit united a select group of industry-leading biologists, chemists, C-level executives, platform tech experts, DMPK and clinical pharmacologists, all tackling the unique challenges of CNS delivered ASOs, siRNAs, miRNAs and saRNAs.
In August 2025, we heard from Alnylam Pharmaceuticals, Denali Therapeutics, Genentech, FDA, Novo Nordisk, Regeneron, Servier, Stoke Therapeutics, Ultragenyx Pharmaceutical and more, to redefine the landscape of oligonucleotide research.
Check Out the 2025 Agenda:
Unpublished insights and never-seen-before data
Two tracked workshop day designed for chemists and biologists
10 new presenting companies including Denali Therapeutics, Alnylam Pharmaceuticals and Novo Nordisk
Regulator presence from Ron Wange, a former FDA expert and author of the non-clinical guidance for oligonucleotides
2025 World-Class Speaker Faculty:
Previously Attending Companies:
What Your Peers Had to Say:
"This summit brings together key stakeholders, including industry leaders, researchers, and regulatory experts, to collaboratively address challenges, share innovative solutions, and explore the transformative potential of oligonucleotide therapeutics in advancing treatment options for CNS disorders"
Nicole Lykens, Director of Neurobiology, Global Nucleic Acid Therapies (GNAT), Novo Nordisk
"CNS is the next frontier in ASO and RNA therapeutics. Attending this conference will provide me, and you, a front row seat to follow the latest achievements, current developments and future aspirations of companies and its stakeholders active in this exciting space"
Jimmy Weterings, Vice President, Head of Oligonucleotide Therapeutics, Bonito Biosciences
2025 Partners:
